Elagolix, a newly developed orally administered drug, was effective in reducing heavy menstrual bleeding in women with uterine fibroids, according to a recent Northwestern Medicine clinical trial.
A new review has found that a combination of endocrine inhibitors and hormone therapy is more effective in prolonging progression-free survival for advanced breast cancer patients, as compared to chemotherapy.
The second annual Women in Medicine symposium brought together Northwestern educators, scientists, trainees and students to highlight pioneering women and challenges still faced today.
A recent campus talk explored how clinical trials of HIV/AIDS drugs in developing countries in the 90s sparked a wealth of discussions about ethics in scientific investigation and barriers to healthcare access.
In a surprising new finding, radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer following surgery.
A gene involved in male hormone production plays a major role in the development of polycystic ovary syndrome, according to a recent study.
A drug called niraparib showed clinically relevant activity in women with relapsed ovarian cancer who had exhausted all previous treatment options, according to a recent study.
Northwestern investigators are building a multi-disciplinary enterprise that is making critical discoveries in maternal-fetal health, with significant clinical implications and real-world consequences.
Northwestern scientists came together to discuss the importance of women’s health research and mark the third anniversary of a landmark sex-inclusion policy by the NIH.
Northwestern scientists have successfully transformed induced pluripotent stem cells into endometrial cells, which line the uterus and are involved in several uterine conditions such as endometrial cancer and infertility.